Last update Dec. 26, 2024

Orphenadrine Citrate

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Orphenadrine is an anatimuscarinic similar to diphenhydramine but without sedative effect; it has spasmolytic, antihistamine and weak local anesthetic properties. It is used in the treatment of muscle spasms and parkinsonism. Oral, intramuscular or intravenous administration.

At the date of last update we found no published data on its excretion in breast milk.

Its pharmacokinetic data (moderately high molecular weight and high percentage of protein binding) make it unlikely that significant amounts will pass into milk.

Product with very few bibliographic references and/or very old, marketed in few countries. Until more published data on this drug in relation to breastfeeding are known, safer alternatives may be preferable, especially during the neonatal period and in case of prematurity.

It should not be used during the first weeks postpartum, since antimuscarinics reduce prolactin production and may interfere with the initial establishment of breastfeeding. (Masala 1982)

If administered during breastfeeding, use minimal doses and monitor for drowsiness and adequate infant feeding and milk production.

Alternatives

  • Baclofen (Safe product and/or breastfeeding is the best option.)
  • Methocarbamol (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Orphenadrine Citrate is also known as


Orphenadrine Citrate in other languages or writings:

Groups

Orphenadrine Citrate belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Orphenadrine Citrate in its composition:

List of 14 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 90 %
Molecular weight 462 daltons
Protein Binding 95 %
Tmax 2 - 4 hours
T½ 13 - 20 hours

References

  1. eMC. Orphenadrine. Drug Summary. 2013 Full text (in our servers)
  2. Rosemont Pharmaceuticals Ltd. Orphenadrine. Drug Summary. 2013 Full text (in our servers)
  3. Farmical. Orfenadrina. Ficha técnica. 2010 Full text (in our servers)
  4. Lee SY, Oh HJ, Kim JW, Kim YG, Moon CJ, Lee EH. Pharmacokinetic study of orphenadrine using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Abstract
  5. Labout JJ, Thijssen Ct, Keijser GG, Hespe W. Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man. Eur J Clin Pharmacol. 1982 Abstract
  6. Masala A, Alagna S, Devilla L, Rovasio PP, Rassa S, Faedda R, Satta A. Muscarinic receptor blockade by pirenzepine: effect on prolactin secretion in man. J Endocrinol Invest. 1982 Jan-Feb;5(1):53-5. Abstract

Total visits

141,742

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM